CN107257684A - 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 - Google Patents

吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 Download PDF

Info

Publication number
CN107257684A
CN107257684A CN201580068592.3A CN201580068592A CN107257684A CN 107257684 A CN107257684 A CN 107257684A CN 201580068592 A CN201580068592 A CN 201580068592A CN 107257684 A CN107257684 A CN 107257684A
Authority
CN
China
Prior art keywords
treatment
body weight
dose
administered
loading dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580068592.3A
Other languages
English (en)
Chinese (zh)
Inventor
何塞普·奥梅德斯-贝格尔
戴维·萨瓦特-利亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecuphar Nv
Original Assignee
Ecuphar Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecuphar Nv filed Critical Ecuphar Nv
Priority to CN202210698831.5A priority Critical patent/CN115154465A/zh
Publication of CN107257684A publication Critical patent/CN107257684A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580068592.3A 2014-10-16 2015-10-13 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途 Pending CN107257684A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210698831.5A CN115154465A (zh) 2014-10-16 2015-10-13 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382396.1A EP3009137A1 (en) 2014-10-16 2014-10-16 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals
EP14382396.1 2014-10-16
PCT/EP2015/073635 WO2016059028A1 (en) 2014-10-16 2015-10-13 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210698831.5A Division CN115154465A (zh) 2014-10-16 2015-10-13 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途

Publications (1)

Publication Number Publication Date
CN107257684A true CN107257684A (zh) 2017-10-17

Family

ID=51844648

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580068592.3A Pending CN107257684A (zh) 2014-10-16 2015-10-13 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途
CN202210698831.5A Pending CN115154465A (zh) 2014-10-16 2015-10-13 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210698831.5A Pending CN115154465A (zh) 2014-10-16 2015-10-13 化合物治疗犬中退行性关节疾病的疼痛和炎症的用途

Country Status (20)

Country Link
US (1) US11154536B2 (enExample)
EP (2) EP3009137A1 (enExample)
JP (1) JP6655625B2 (enExample)
CN (2) CN107257684A (enExample)
AR (1) AR102295A1 (enExample)
CA (1) CA2964428C (enExample)
CY (1) CY1123243T1 (enExample)
DK (1) DK3206684T3 (enExample)
ES (1) ES2828435T3 (enExample)
HR (1) HRP20201233T1 (enExample)
HU (1) HUE050511T2 (enExample)
LT (1) LT3206684T (enExample)
MX (1) MX376725B (enExample)
PL (1) PL3206684T3 (enExample)
PT (1) PT3206684T (enExample)
RS (1) RS60777B1 (enExample)
SI (1) SI3206684T1 (enExample)
SM (1) SMT202000415T1 (enExample)
TW (1) TWI707678B (enExample)
WO (1) WO2016059028A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109303784B (zh) * 2018-09-30 2020-06-23 山东省文登整骨医院 痛风性关节炎动物模型的构建方法
TWI875757B (zh) * 2019-05-08 2025-03-11 瑞士商諾華公司 T1dm和胰島炎治療中使用之抗cd40抗體
EP4029502A1 (en) 2021-01-15 2022-07-20 Ecuphar N.V. Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
US12208085B2 (en) 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1307566A (zh) * 1998-05-29 2001-08-08 埃斯蒂文博士实验室股份有限公司 吡唑啉衍生物、它们的制备方法和作为药物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773615B2 (en) * 1997-05-05 2004-05-27 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
KR20070110077A (ko) * 2005-03-10 2007-11-15 제넨테크, 인크. 혈관 완전성을 조정하기 위한 방법 및 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1307566A (zh) * 1998-05-29 2001-08-08 埃斯蒂文博士实验室股份有限公司 吡唑啉衍生物、它们的制备方法和作为药物的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
P.L.TOUTAIN等: "A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide,a Cox-2 selective nonsteroidal anti-in¯ammatory drug in the dog", 《JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS》 *
RAQUEL F. REINOSO等: "Pharmacokinetics of E-6087, a New Anti-inflammatory Agent, in Rats and Dogs", 《BIOPHARMACEUTICS & DRUG DISPOSITION》 *
S. R. COX等: "The pharmacokinetics of mavacoxib, a long‐acting COX‐2 inhibitor, in young adult laboratory dogs", 《JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS》 *

Also Published As

Publication number Publication date
HUE050511T2 (hu) 2020-12-28
CN115154465A (zh) 2022-10-11
EP3009137A1 (en) 2016-04-20
EP3206684B1 (en) 2020-06-17
CY1123243T1 (el) 2021-10-29
AR102295A1 (es) 2017-02-15
US11154536B2 (en) 2021-10-26
PT3206684T (pt) 2020-08-24
MX2017004899A (es) 2018-02-12
JP6655625B2 (ja) 2020-02-26
ES2828435T3 (es) 2021-05-26
RS60777B1 (sr) 2020-10-30
US20170231961A1 (en) 2017-08-17
DK3206684T3 (da) 2020-08-10
HRP20201233T1 (hr) 2020-11-13
CA2964428C (en) 2022-01-04
TWI707678B (zh) 2020-10-21
SI3206684T1 (sl) 2020-11-30
CA2964428A1 (en) 2016-04-21
LT3206684T (lt) 2020-10-12
JP2017531042A (ja) 2017-10-19
WO2016059028A1 (en) 2016-04-21
EP3206684A1 (en) 2017-08-23
TW201625239A (zh) 2016-07-16
PL3206684T3 (pl) 2021-01-11
SMT202000415T1 (it) 2020-11-10
MX376725B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
US10450302B2 (en) Methods of treating inflammation or neuropathic pain
JP2021102634A (ja) 絶食条件下でのタシメルテオンの投与
Eeckhaut et al. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics
Kutlar et al. A dose‐escalation phase IIa study of 2, 2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease
JP2007302657A (ja) 痙症の兆候および症候の緩和方法
CN107257684A (zh) 吡唑啉衍生的化合物及其以每周用量方案针对源自哺乳动物中的退行性关节疾病的炎症和疼痛的用途
Friton et al. Efficacy and safety of injectable robenacoxib for the treatment of pain associated with soft tissue surgery in dogs
CN107890476A (zh) 用于使时钟基因的表达变化的组合物
Percy Rett syndrome: coming to terms with treatment
Casey Arthritis: joints inflamed
Straticò et al. Analgesic effect of Butorphanol during Castration in Donkeys under total intravenous anaesthesia
JP2005530751A5 (enExample)
Lascelles Supportive care for the cancer patient
JP2020530011A (ja) バイオ治療薬としてのストレプトコッカス・オーストラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ａｕｓｔｒａｌｉｓ）
WO2015084706A1 (en) Intra-articular formulations and methods for treatment of osteoarthritis
McKune Clinical Management and Pharmacologic Treatment of Pain
Pucheu et al. Multicentric, randomized and positive-controlled study to assess the efficacy of an association of chondroitin sulphate, chitosan, l-selenomethionine and epigallocatechin-3-gallate in the control of osteoarthritis and functional postoperative recovery
Smith et al. Treatment of equine joint diseases Part 1: Pharmacological management of equine osteoarthritis (OA)
US20100203146A1 (en) Intermittent dosing strategy for treating rheumatoid arthritis
Tarquinio et al. Targeted treatments in Rett syndrome
JP2017507941A (ja) 機械的な神経損傷を処置するための新規組成物
SARAFZADEH et al. Thiopental sodium anesthesia following premedication of rabbits with vitamin C
AU2020263152A1 (en) Compositions and methods for potentiating derivatives of 4-Aminophenols
Spelts et al. Pain Management
LASCELLES Supportive Care for

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171017

RJ01 Rejection of invention patent application after publication